Program
The interactive Breakthroughs in Muscular Dystrophy (November 19-20, 2024) program below is updated live as speakers and sessions are confirmed.
Ready to Register?
Register now!
Program
Tuesday, November 19
Attendee Breakfast
7:30 - 8:30 a.m.
Opening Remarks from Jeffrey Chamberlain, PhD
8:30 - 8:35 a.m.
Keynote - Genetic Therapies for Muscular Dystrophies: Opportunities and Challenges
8:35 - 9:35 a.m.
Chair: Jeffrey Chamberlain, PhD, University of Washington
- Cloning the Duchenne Gene - An Origin Story
Louis Kunkel, PhD, Children's Hospital Boston
- Clinical Aspects of Gene Therapies for Muscular Dystrophies - Challenges and Opportunities
Carsten Bönnemann, MD, NINDS/NIH
Non-Viral Delivery
9:35 - 10:35 a.m.
Chair: Monkol Lek, PhD, Yale School of Medicine
- Advancing Non-Viral Delivery via Battelle's HIT SCAN Platform
Kenneth Sims, PhD, Battelle Memorial Institute
- A targeted, non-viral platform to deliver the full-length dystrophin gene
Nick Whitehead, PhD, Myosana Therapeutics
Coffee Break (Paid Presentation) + Exhibits
10:35 - 11:05 a.m.
Viral Delivery
11:05 a.m. - 12:05 p.m.
Chair: Melissa Spencer, PhD, UCLA
- Monitoring Viral Delivery with Non-invasive Imaging
Oluwatayo Ikotun, University of California, Los Angeles
- Split-Inteins
Jeffrey Chamberlain, PhD, University of Washington
Attendee Lunch + Exhibits
12:05 - 1:05 p.m.
Monitoring AAV Delivery
1:05 - 2:30 p.m.
Chair: Carsten Bönnemann, MD, NINDS/NIH
- Intro to Monitoring AAV Delivery
Federico Mingozzi, PhD, Spark Therapeutics Inc
-
Vector Immunology
J. Fraser Wright, PhD, Stanford School of Medicine
-
Modeling and Tolerizing Dystrophin Immunity in Mice
Armando Villalta, PhD, UC Irvine
-
Enabling Readministration/Redosing
Barry Byrne, MD, PhD, University of Florida
Coffee Break + Exhibits
2:30 - 2:40 p.m.
Gene Editing
2:40 - 3:30 p.m.
Chair: Angela Lek, PhD, VP of Research, MDA
- A Novel Dual Vector Approach for Safe and Efficient Expression of Large Genes using RNA End-joining (REJ)
Samuel Pfaff, PhD, The Salk Institute for Biological Studies
- Genome Editing for Duchenne Muscular Dystrophy
Charles Gersbach, PhD, Duke University
Coffee Break (Paid Presentation) + Exhibits
3:30 - 4 p.m.
Oral Abstract Session
4 - 5:45 p.m.
Chairs: Evrim Atas, PhD and Angela Lek, PhD MDA
-
1. Editing of Postmitotic Muscle and Satellite Cells for Continuous Correction of Dystrophin Expression in Duchenne Muscular Dystrophy
Niclas Bengtsson, PhD, University of Washington
-
2. CSF Delivery of INS1201 AAV9-Micro-Dystrophin as a Potential Therapy for DMD
Gretchen Thomsen, PhD, Insmed, Inc.
-
3. Therapeutic Potential of ENTR-601-44, an Endosomal Escape Vehicle (EEVTM) - Oligonucleotide Conjugate for the Treatment of Exon 44 skip Amenable DMD
Mahasweta Girgenrath, PhD, Entrada Therapeutics Inc
-
4. Development of Gene Therapy for LGMD-R9
Evelyne Gicquel, PhD, Genethon
-
6. GNT0004, Genethon's AAV8 Vector-delivered Microdystrophin Gene Therapy for Duchenne Muscular Dystrophy: First Data from Phase 1/2 Part of GNT-016-MDYF All-in-one Clinical Trial in Ambulant Boys
Serge Braun, PhD, AFM TELETHON / GENETHON
-
58. RGX-202, an Investigational Gene Therapy for the Treatment of Duchenne Muscular Dystrophy: Interim Clinical Data
Jahannaz Dastgir, DO, REGENXBIO Inc.
-
5. The Venture Philanthropy Model of Drug Development - Working with Non-Profit Foundations and Governments from Concept to Drug Approval
Eric Hoffman, PhD, Binghamton University
Poster Reception + Exhibits
5:45 - 7 p.m.
Poster Hall 1: Great Lakes Room
- 7. U7snRNA as a Tool for Restoring Dystrophin Expression in Patients with Exon 17 Skip-Amenable Deletions
Liubov Gushchina, PhD, The Ohio State University and Nationwide Children's Hospital RI
- 8. KT809 Dose-Dependently Improves Muscle Function in a Severe DMD Mouse Model and Results in High and Uniform Microdystrophin Expression in the Heart and Skeletal Muscles of Non-Human Primates
Chady Hakim, PhD, Kate Therapeutics
- 9. Full-Length Dystrophin Gene Delivery Using Triple MyoAAV Vectors
Renzhi Han, PhD, Indiana University School of Medicine
-
11. (Withdrawn) CRISPR/hfCas12Max DNA Editing Therapy Restores Dystrophin Protein and Muscle Functions in Duchenne Muscular Dystrophy
Guoling Li, PhD, HuidaGene Therapeutics Co., Ltd
-
12. (Withdrawn) Precise Correction of Duchenne Muscular Dystrophy via Exon-Skipping Using Compact Base Editor
Guoling Li, PhD, HuidaGene Therapeutics Co., Ltd
- 13. A Comparative Analysis of Long-Term and Short-Term Outcomes of AAV-CRISPR Treatment in a Canine Model of Duchenne Muscular Dystrophy
Rika Maruyama, PhD, University of Alberta
-
14. (Virtual) Rational Design and Rigorous Testing of Novel, Non-Immunogenic Dystrophin Mimetics Providing Superior Cardioprotection and Biomechanical Stability in vivo
Hansell Stedman, MD, University of Pennsylvania
- 15. Wearable Device Outcomes From EMBARK, a Pivotal Phase 3 Study in Patients With Duchenne Muscular Dystrophy Treated With Delandistrogene Moxeparvovec
Paul Strijbos, PhD, F. Hoffmann-La Roche Ltd
- 16. Turbo-Charging Gene Therapy for Genetic Muscle Disorders using Novel Transcriptional Cis-Regulatory Elements
Thierry Vandendriessche, PhD, Free University of Brussels (VUB)
- 18. Development of Pilot Potency Assessments for MyoDys45-55, a Gene Editing Therapy for Duchenne Muscular Dystrophy
Courtney Young, PhD, MyoGene Bio
- 19. (Virtual) A Transformative DMD Cytosine Base Editing Drug
Chunyan He, PhD, Suzhou GenAssist Thx
- 20. (Virtual) Drug Metabolism and Pharmacokinetics in Mice Systemically Administrated with a Base Editing Drug for Duchenne Muscular Dystrophin (DMD)
Chunyan He, PhD, Suzhou GenAssist Thx
- 21. Screening of Treatment-Emergent Anti-Dystrophin Antibodies: A Validated, Regulatory-Compliant LIPS Assay Covering 100% of Dystrophin
Eric Hoffman, PhD, Binghamton University
- 22. Development of a 248 Kilodalton Midlength-Dystrophin Gene Therapy for DMD using an AAV-Based RNA End-Joining Approach
Gretchen Thomsen, PhD, Insmed, Inc.
- 23. Optidys, a New Gene Therapy Product for Duchenne Muscular Dystrophy, Shows Therapeutic Potential and Advantage over Current Treatments
Evelyne Gicquel, PhD, Genethon
- 24. AUF1 Gene Therapy for DMD Increases Durable Endogenous Utrophin Expression, Muscle Regeneration, Muscle Function Performance and Synergizes With Microdystrophin Therapy
Dounia Abbadi, PhD, NYU School of Medicine
- 25. AUF1 Gene Therapy Restores Muscle Morphology and Function in Limb Girdle Muscular Dystrophy Recessive 1 (LGMDR1, calpainopathy)
Dounia Abbadi, PhD, NYU School of Medicine
- 26. An Engineered AAV Targeting Integrin Alpha V Beta 6 Presents Improved Myotropism Across Species
Anthony Brureau, PhD, GENETHON
- 27. Overcoming Phenotypic Variability in Dystrophic Models: A Machine Learning Method for Refined Gene Therapy Evaluation
Anthony Brureau, PhD, GENETHON
- 28. A Universal Approach to Potency Assay Development for AAVs Delivering Micro-RNAs
Jason McCoy, PhD, Nationwide Children's Hospital
- 29. Developing a Second Generation Proviral Plasmid to Reduce Aberrant Cross Packaging and ITR Promoter Activity in AAV Vector Preparations
Pranali Mistry, Nationwide Children's Hospital
- 30. CRISPR-Cas13d Gene Therapy for Facioscapulohumeral Muscular Dystrophy
Kate Neal, Nationwide Children's Hospital
- 31. Development of KT323 as a Potent and Safe Gene Therapy Candidate for Facioscapulohumeral Muscular Dystrophy (FSHD) Through High Throughput AAV Capsid and Cargo Engineering
Saurav Seshadri, PhD, Kate Therapeutics
- 32. Efficient Expression of Full-Length SMCHD1 in Muscles Using Split Inteins
Merlin Premalatha Thangaraj, PhD, Nationwide Children's Hospital
- 33. (Virtual) The Prevalence of Sleep Disorders among Individuals with Muscular Dystrophy: A Review of the Literature
Nedra Whitehead, PHD, CGC, RTI International
-
34. (Virtual) BIN1 Gene Replacement Reverts BIN1-Related Centronuclear Myopathy in a Preclinical Model
Jocelyn Laporte, PhD, CERBM IGBMC
-
35. Functional Benefit of CRISPR/Cas9-Induced Deletion for RYR1 Dominant Mutation
Isabelle Marty, PhD, Inserm
Poster Hall 2: Ontario and Erie Rooms
- 36. Correcting Mutations in the DYSF Gene Using Prime Editing
Jacques Tremblay, PhD, Université Laval and CRCHUQ
- 37. Multiplex Base Editing in Primary Human Muscle Stem Cells to Address Compound Heterozygous Muscular Dystrophy
Supriya Krishna, MDC Berlin
- 38. Functional Efficacy of SRP-9004 in Young and Aged LGMD2D/R3 Mice
Luke Lemmerman, PhD, Sarepta Therapeutics, Inc.
- 39. Patient-derived stem cells for in vitro modeling of LAMA2-related Congenital Muscular Dystrophy
Jaquelyn Villalba, Cedars-Sinai Medical Center
- 40. AAV Delivery of ADAR Mediated RNA Editing for Treatment of Collagen VI Related Muscular Dystrophy
Russell Butterfield, MD, PhD, University of Utah
- 41. Etiology of a Mouse Model of CHKB mediated muscular dystrophy - A Platform for Gene Therapy for Disorders of Lipid Synthesis
Christopher McMaster, PhD, Dalhousie University
- 42. Treatment of a Severe DM1 Mouse Model with Verapamil, Amlodipine, and Ranolazine
Lily Cisco, University of Rochester
- 43. Splicing is improved using a novel AAV-microRNA delivery platform as a treatment for Myotonic Dystrophy Type 1
Martin Goulet, PhD, Sanofi
- 44. Enhancing Antisense Oligonucleotide Efficacy Using Small Molecule Oligonucleotide Activity Enhancers (OAEs)
Saeed Anwar, University of Alberta
- 45. Development of a New DUX4-Responsive Reporter Mouse
Jessica Camp, Nationwide Children's Hospital
- 46. Spatial Transcriptomic Characterization of an AAV-DUX4 Mouse Model of FSHD Identifies Focal and Widespread Cell Type Expression Changes in Muscle
Joel Chamberlain, PhD, University of Washington School of Medicine
- 47. Development and Characterization of a Minipig Model of Facioscapulohumeral Muscular Dystrophy (FSHD)
Chris Rogers, PhD, Exemplar Genetics
- 48. Human Stem Cell-derived Engineered Skeletal Muscle Tissues to Test Epigenetic Modulators and Deimmunized Gene Transfer Strategies for Duchenne Muscular Dystrophy
David Mack, PhD, University of Washington Medicine
- 49. Delandistrogene Moxeparvovec Promoter Activity in Human Cardiomyocytes and Cardiac Safety Assessment in Mice and Nonhuman Primates
Stephen Baine, PhD, Sarepta Therapeutics
- 50. Reduction of Dystrophin-Targeting microRNAs Increases Expression of Clinically Relevant Dystrophin Isoforms
Alyson Fiorillo, PhD, Virginia Commonwealth University
- 51. Template-Assisted Sequence Knock-In Rescues a Deletion Model of Duchenne Muscular Dystrophy
Sina Fatehi Someeh, The Hospital for Sick Children (SickKids)
- 52. Correction of DMD Exon 45 Deletion Using Homology-Independent Targeted Integration
Stefan Nicolau, MD, Nationwide Children's Hospital
- 53. Ultrasound-Mediated Delivery of Non-Viral Gene Therapy Payloads to Skeletal and Cardiac Muscles in Mice and Non-Human Primates
Ivan Krivega, PhD, SonoThera
- 54. Bioengineered Synthetic Chromosomes as Therapeutics for Muscular Dystrophies
Edward Perkins, PhD, CarryGenes Bioengineering
- 55. Exon 45 Skipping and Dystrophin Production with ENTR-601-45 in Preclinical Models of Duchenne Muscular Dystrophy
Amy Hicks, PhD, Entrada Therapeutics
- 56. A Synergistic Oligonucleotide Therapy to Improve Muscle Health and Dystrophin Restoration in Duchenne Muscular Dystrophy
James Novak, PhD, Children's National Hospital
- 57. A Novel IP-Mass Spectrometry Method to Characterize the Dystrophin Associated Protein Complex in Skeletal Muscle
Emily Canessa, Binghamton University
- 59. (Virtual) Cellular Mapping of DMD Transcript in Human Myogenic Cells and Skeletal Muscle by RNA in Situ Hybridization and Multiphoton Imaging
Alessandra Ferlini, MD, PhD, University of Ferrara
- 60. Gene Transfer to Muscle Using HSV Vectors
Selene Ingusci, PhD, University of Pittsburgh
- 61. Correction of Nonsense Variants in DMD Using AAV-Compatible Base and Prime Editing
Ryan Marks, The Hospital for Sick Children
- 62. Extensor Digitorum Brevis Feasibility for Cell-Based Therapy for Duchenne Muscular Dystrophy
John Martone, University of Minnesota
-
63. (Virtual) Transcriptomics Reveals DMD Driven Cell Dynamics and Mechanisms of Myofiber Death and Innate Immune Memory in Human Dystrophic Muscle; Potential Barriers to Microdystrophin Gene Therapy
Stanley Nelson, MD, UCLA
- 64. Development of Functionalized Lipid Nanoparticles for Enhanced Micro-Dystrophin Delivery in Duchenne Muscular Dystrophy Therapy
Andrea Pirrottina, University of Rome
-
65. A Novel Engineered Membrane Repair Protein Therapeutic Increases Sarcolemma Repair by Producing Phosphatidylserine Binding in Models of Duchenne Muscular Dystrophy
Noah Weisleder, PhD, University of Kentucky
-
66. Prime Editing Permits to Correct Point Mutations Responsible for Many Muscular Dystrophies
Jacques Tremblay, PhD, Université Laval and CRCHUQ
-
67. Combinatorial in vitro and in vivo Phage Display Methodology to Identify Skeletal Myocyte Targeting Cell Penetrating Peptides
Maliha Zahid, MD, PhD, Mayo Clinic
Wenesday, Novemeber 20
Attendee Breakfast
7:30 - 8:30 a.m.
RNA Targeted Therapies
8:30 - 10:15 a.m.
Chair: Scott Harper, Ohio State University & Nationwide Children's Hospital
- Enhancing the Delivery of Antisense Oligonucleotide Therapies: Innovative Approaches for Muscular Dystrophy
Toshifumi Yokota, PhD, University of Alberta, Edmonton, AB
- Translating RNAi-based Gene Therapies for Dominant Neuromuscular Disorders
Lindsay Wallace, PhD, Nationwide Children's Research Institute, Columbus, OH
- RNA Therapies to Investigate the Impact of Dystrophin Restoration in the CNS of Dystrophic Mouse Models
Aurelie Goyenvalle, PhD, University of Versailles Saint Quentin En Yvelines
- Panel Discussion
Coffee Break (Paid Presentation)
10:15 - 10:45 a.m.
Panel: Future of Genetic Therapies for Muscular Dystrophies
10:45 a.m. - 12 p.m.
Chair: Sharon Hesterlee, Chief Research Officer, Muscular Dystrophy Association
- Panelists
Jeffrey Chamberlain, PhD, University of Washington
Carsten Bönnemann, MD, NINDS/NIH
Katherine High, MD, Rockefeller University
Barry Byrne, MD, PhD, University of Florida
Melissa Spencer, PhD, UCLA
Ready to Register?
Register now!
Thank You to the Organizing Committee
- Jeffrey Chamberlain, PhD
University of Washington
- Angela Lek, PhD
Muscular Dystrophy Association
- Evrim Atas, PhD
Muscular Dystrophy Association
- Charlie Gersbach, PhD
Duke University
- Toshifumi Yokota, PhD
University of Alberta
- Manuela Corti, PhD
University of Florida
- Monkol Lek, PhD
Yale University
- Julie Crudele, PhD
University of Washington
- Melissa Spencer, PhD
UCLA
- Carsten Bönnemann, MD
NIH
- Scott Harper, PhD
The Ohio State University/Nationwide Children's Hospital